Chronic Lymphocytic Leukemia (CLL) – Adult (Greater than or equal to 18 years old)

INITIAL EVALUATION

TREATMENT

- Young/fit IGVH- Mutated
  - FCR
- Young/fit IGVH- Unmutated
  - Ibrutinib
- Elderly/comorbidities
  - Chlorambucil plus obinutuzumab (or ofatumumab)
  - Ibrutinib
- Del(17p) (any age)
  - Ibrutinib
- Clinical trial

SURVEILLANCE

- Relapsed/Refractory Non-Del(17e)
  - Ibrutinib
  - Idelalisib plus rituximab
  - Clinical trial
- Del(17p)
  - Venetoclax
  - Ibrutinib

NOTE: Consider clinical trials as treatment options for eligible patients. Leukemia patients should be referred and treated at a Comprehensive Cancer Center.

IGVH (Immunoglobulin heavy-chain variable-region)
FCR (Fludarabine, Cyclophosphamide and Rituximab)
1Leukemia Newsletter http://www.mdanderson.org/leukemia

Copyright 2016 The University of Texas MD Anderson Cancer Center

NOTE: This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson’s specific patient population; MD Anderson’s services and structure; and MD Anderson’s clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.


Chronic Lymphocytic Leukemia (CLL) – Adult

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson’s specific patient population; MD Anderson’s services and structure; and MD Anderson’s clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This practice guideline is based on majority expert opinion of the Leukemia Center Faculty at the University of Texas, MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following medical oncologists.

- Michael Andreeff, MD
- Gautam Borthakur, MD
- Jan Burger, MD
- Jorge Cortes, MD
- Zeev Estrov, MD
- Alessandra Ferrajoli, MD
- Emil Freireich, MD
- Guillermo Garcia-Manero, MD
- Yoliette Goodman, MBA
- M. Kantarjian, MD
- Firoze Jameel, OCN, RN
- Tapan Kadia, MD
- Michael Keating, MD
- Marina Konopleva, MD
- Steven Kornblau, MD
- Farhad Ravandi-Kashani, MD
- Michael Rytting, MD
- Srdan Verstovsek, MD
- William Wierda, MD

† Physician Leads
* Clinical Effectiveness Development Team